Accurately Controlled Delivery of Temozolomide by Biocompatible UiO-66-NH2 Through Ultrasound to Enhance the Antitumor Efficacy and Attenuate the Toxicity for Treatment of Malignant Glioma
DOI: https://doi.org/10.2147/IJN.S330187
IF: 7.033
2021-10-09
International Journal of Nanomedicine
Abstract:Zhiping Wan, 1, &ast Chunlin Li, 2, &ast Jinmao Gu, 1, &ast Jun Qian, 1 Junle Zhu, 1 Jiaqi Wang, 2 Yinwen Li, 2 Jiahao Jiang, 1 Huairui Chen, 1 Chun Luo 1 1 Department of Neurosurgery, Tongji Hospital, School of Medicine, Tongji University, Shanghai, 200092, People's Republic of China; 2 Trauma Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China &astThese authors contributed equally to this work Correspondence: Chun Luo; Huairui Chen Email ; Background: Glioma is the most common and malignant primary brain tumour in adults and has a dismal prognosis. Temozolomide (TMZ) is the only clinical first-line chemotherapy drug for malignant glioma up to present. Due to poor aqueous solubility and toxic effects, TMZ is still inefficient and limited for clinical glioma treatment. Methods: UiO-66-NH 2 nanoparticle is a zirconium-based framework, constructed by Zr and 2-amino-1,4-benzenedicarboxylic acid (BDC-NH 2 ) with octahedral microporous structure, which can be decomposed by the body into an ionic form to discharge. We prepared the nanoscale metal-organic framework (MOF) of UiO-66-NH 2 to load TMZ for therapy of malignant glioma, TMZ is released from UiO-66-NH 2 through a porous structure. The ultrasound accelerates its porous percolation and promotes the rapid dissolution of TMZ through low-frequency oscillations and cavitation effect. The biological safety and antitumor efficacy were evaluated both in vitro and in vivo. Results: The prepared exhibited excellent biocompatibility and biosafety due to minimal drug leakage without ultrasound intervention. We further used the flank model of glioblastoma to verify the in vivo therapeutic effect. 2 nanocomposites could be well delivered to the tumour tissue, which led to local enrichment of the TMZ concentration. Furthermore, 2 nanocomposites under ultrasound demonstrated much more efficient inhibition for tumor growth than 2 nanocomposites and TMZ alone. Meanwhile, the bone marrow suppression side effects of TMZ were significantly reduced by 2 nanocomposites. Conclusion: In this work, 2 nanocomposites with ultrasound mediation could effectively improve the killing effect of malignant glioma and decrease TMZ-induced toxicity in normal tissues, demonstrating great potential for the delivery of TMZ in the clinical treatment of malignant gliomas. Keywords: MOF, TMZ, ultrasound glioma The prognosis is extremely poor for malignant gliomas, especially glioblastoma (GBM), which account for approximately 47.7% of brain malignant tumours. 1 At present, the main treatment protocol is surgical adjuvant radiotherapy and chemotherapy. Postoperative temozolomide (TMZ) adjuvant chemotherapy is a common clinical treatment among the few available treatments for glioblastoma. However, it lacks selectivity and has an insufficient brain tumour focal concentration, which leads to very limited therapeutic effect and causes a series of side effects in clinical applications. Among these side effects, haematopoietic suppression has become the most severe problem associated with TMZ. 2 Thus, it is necessary to develop a new strategy to precisely deliver and release TMZ in the tumour region. With the rapid development of nanotechnology, organic and inorganic delivery nanocarriers, such as inorganic nanoparticles, liposomes, polymeric nanoparticles and so on, have been widely used as selective delivery of drugs in the treatment of tumours. 3 In recent years, MOFs have been widely developed as vehicles for effective delivery of drugs to tumour tissues. MOFs is a new class of crystalline porous materials constructed by metal ions/clusters and organic linkers. 4 Due to internal circulation stability, high loading capacity, and excellent biocompatibility, MOFs provide an unprecedented opportunity for the treatment of cancer. 5 Especially, the nanoscale MOF of UiO-66-NH 2 can be as an ideal drug-delivery nanoparticle because it has superior cavity volume and slow-release functions, 6 which is expected to penetrate the blood–brain barrier (BBB). UiO-66-NH 2 nanoparticle is a zirconium-based framework constructed by Zr and 2-amino-1,4-benzenedicarboxylic acid (BDC-NH2) with octahedral microporous structure, exhibiting great chemical and thermal stability. 4 To design MOF nanocomposites as carriers for controllable drug release, various factors such as hydrophobicity, pH, temperature, biomolecula -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology